CD19-BCMA Targeted CAR-T Dose 2

Phase 1Cell therapy

CD19-BCMA Targeted CAR-T Dose 2 is one of 48 small molecule programs targeting Myasthenia Gravis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisActive, not recruiting

Myasthenia GravisPhase 1

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Ultomiris

AstraZeneca

Phase 3

5 3

Vyvgart

Argenx

Phase 3

17 4

Soliris

AstraZeneca

Phase 3

4 5

Cellcept

Roche

Phase 3

4 6

Zilbrysq

UCB

Phase 3

4 7

Fabhalta

Johnson & Johnson

Phase 3

3 8

Rhapsido

Novartis

Phase 3

1 9

Arava

Sanofi

Phase 3

1 10

ENSPRYNG

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Myasthenia Gravis

NCT06371040

Clinical

Trials by Indication[1]

Myasthenia Gravis1 trial

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

Recruiting·TTing Chang, MD·Phase 1·NCT06371040·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD19-BCMA Targeted CAR-T Dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19-BCMA Targeted CAR-T Dose 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19-BCMA Targeted CAR-T Dose 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ting Chang, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TTing Chang, MD

CD19-BCMA Targeted CAR-T Dose 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News